Candel Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
CADL Nasdaq 2830 www.candeltx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Candel Therapeutics, Inc.

Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors - Sep 10th, 2026 6:05 am
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sep 1st, 2026 2:05 pm
Oncolytic Virus Cancer Therapy Market Expected to Expand Rapidly During the Forecast Period (2026-2036) Amid Rising Investments in Next-Generation Cancer Treatments| DelveInsight - Aug 26th, 2026 8:41 am
Candel Therapeutics to Present at September Investor Conferences - Aug 26th, 2026 6:05 am
Candel Therapeutics (CADL) Is Up 5.4% After Steep Q2 Loss Widening Has The Bull Case Changed? - Aug 21st, 2026 2:09 pm
Candel Therapeutics (CADL) Faces Bigger Losses As Its Valuation Still Looks Pricey - Aug 20th, 2026 10:14 am
Non-Metastatic Prostate Cancer Market to Exhibit Growth at a CAGR of 4% During the Forecast Period (2026-2036), as Pharmaceutical Companies Intensify Development of Advanced Therapies | DelveInsight - Aug 18th, 2026 8:33 am
CADL Rises As Biotech Eyes First Commercial Product in 2027 — CEO Points To ‘Meaningful Execution’ Toward BLA Submission In Q4 - Aug 13th, 2026 1:27 pm
Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights - Aug 13th, 2026 6:05 am
CADL Stock In Focus As Candel Nears Year-End BLA Filing For Prostate Cancer Drug — Eyes $10–$16B Opportunity - Aug 12th, 2026 1:08 pm
Candel Therapeutics Eyes 2026 Prostate Cancer Filing as Lung Study Ramps Up - Aug 12th, 2026 11:04 am
Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026 - Aug 3rd, 2026 6:05 am
Candel Therapeutics to Present at Canaccord Genuity’s 46th Annual Growth Conference in Boston - Jul 29th, 2026 6:05 am
Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Jul 8th, 2026 2:05 pm
CADL Stock Heads For Biggest Monthly Gains Since December 2024 – Retail Says ‘Our SLS Days Are Coming’ - Jun 30th, 2026 10:27 am
Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors - Jun 30th, 2026 6:05 am
Candel Therapeutics Designates Mark Sims as CCO - Jun 25th, 2026 1:53 pm
Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer - Jun 25th, 2026 6:05 am